REG - OptiBiotix Health - SlimBiome study update

OptiBiotix HealthAnnouncement

10/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241010:nRSJ6136Ha&default-theme=true

RNS Number : 6136H  OptiBiotix Health PLC  10 October 2024

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

SlimBiome study update

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces further positive study results.

 

The Company has completed a fourth human study on SlimBiome®, which followed
recommended industry guidelines and was designed to investigate the acute
impact of a single dose of SlimBiome® in the presence of 50g sugar (12
teaspoons) on 20 overweight volunteers on their glycaemic response, hunger,
and cravings. Feelings of hunger, fullness, desire to eat, and amount of food
desired were assessed at 0, 75 and 150min using the visual analogue scale, a
validated questionnaire used in nutrition research to assess appetite and food
intake.

 

The researchers at the Brunel University of London reported results showing
significant impact on multiple parameters important to appetite and hunger
regulation including: -

 

·      A statistically significant reduction (26.85%) in hunger
(p=0.007) with the intake of SlimBiome®

·      Participants were approximately seven times less hungry when
taking SlimBiome® compared to sugar

·      A statistically significant increase (46.9%) in fullness compared
to baseline (p=0.009)

·      Participants were approximately two times fuller when taking
SlimBiome® compared to sugar

 

No safety, compliance, or tolerance issues were reported by volunteers. The
results of this study are aligned with the Company's earlier study on the
acute impact of SlimBiome® in healthy weight volunteers and provide further
evidence of the ability of a single dose of SlimBiome® to moderate the impact
of the ingestion of a large amount of sugar on appetite related parameters and
support fullness. Researchers at the University of Nottingham report that in
stomach simulation laboratory experiments, SlimBiome resulted in a six-fold
increase in viscosity when taken with sugar and in a 9.6-fold increase in
viscosity when taken with a meal replacement which is related with the ability
of SlimBiome to support the feeling of fullness and reduce hunger.

 

The results are consistent with consumer feedback and customer product reviews
who report feeling less hungry leading to reduced snacking and lower food
intake leading to an average weight loss of 1.2kg per week.

 

These findings show SlimBiome® can have a role as a functional ingredient by
itself as in SlimBiome Medical®, in meal replacements as in GoFigure®, or as
part of a healthy snack in controlling hunger and desire to eat as part of a
calorie controlled diet.

 

Stephen O'Hara, CEO of OptiBiotix Health plc commented: "We are delighted that
this additional study of SlimBiome® has further cemented its role as a
functional ingredient either standalone or as part of a calorie controlled
diet aimed at weight loss.

 

"Moreover, we note the recent positive trading update from ProBiotix Health.
As the largest shareholder of ProBiotix Health, we are pleased to see their
strong sales figures and balance sheet. In our interim results released in
September, we also reported a significantly increased order book and solid
sales performance for the first half of the year, and the strong strategic and
commercial progress we achieved in this period has continued in the second
half to date.

 

"We are confident that our strategy will deliver an improved sales performance
for the rest of this year, and will continue in 2025, and look forward to
demonstrating the long-term growth potential of the Group."

 

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman           Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)                                Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)                                 Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                                     Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDMLBRTMTJMBAI